Naslov
Differences in Plasma Cannabidiol Concentrations in Women and Men: A Randomized, Placebo-Controlled, Crossover Study

Autori
Batinic, Ana ; Sutlovic, Davorka ; Kuret, Sendi ; Burcul, Franko ; Kalajzic, Nina ; Matana, Antonela ; Dujic, Goran ; Vrdoljak, Josip ; Kumric, Marko ; Bozic, Josko ; Dujic, Zeljko

Vrsta, podvrsta
Radovi u časopisima, znanstveni

Izvornik
International Journal of Molecular Sciences (2023)

Status rada
Online first

Ključne riječi
CBD metabolites ; Dehydra ; TECH2.0 CBD ; LC-MS analysis ; SNP genotyping

Sažetak
The potential therapeutic benefits of cannabidiol (CBD) require further study. Here, we report a triple-blind (participant, investigator, and outcome assessor) placebo-controlled crossover study in which 62 hypertensive volunteers were randomly assigned to receive the recently developed DehydraTECH2.0 CBD formulation or a placebo. This is the first study to have been conducted using the DehydraTECH2.0 CBD formulation over a 12-week study duration. The new formulation's long-term effects on CBD concentrations in plasma and urine, as well as its metabolites 7-hydroxy-CBD and 7-carboxy-CBD, were analyzed. The results of the plasma concentration ratio for CBD/7-OH-CBD in the third timepoint (after 5 weeks of use) were significantly higher than in the second timepoint (after 2.5 weeks of use ; p = 0.043). In the same timepoints in the urine, a significantly higher concentration of 7-COOH-CBD was observed p < 0.001. Differences in CBD concentration were found between men and women. Plasma levels of CBD were still detectable 50 days after the last consumption of the CBD preparations. Significantly higher plasma CBD concentrations occurred in females compared to males, which was potentially related to greater adipose tissue. More research is needed to optimize CBD doses to consider the differential therapeutic benefits in men and women.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA